Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced the winners of the third annual Regeneron Prize for Creative Innovation, an award designed to acknowledge, reward and foster talented early-career biomedical scientists. This year, Regeneron awarded $155,000 in prize money to 10 awardees and two institutions.
“The winners of the Regeneron Prize for Creative Innovation are exemplary young scientists whose intelligence and unconventional thinking empower them to lead the next generation of biomedical discovery,” said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Laboratories and Chief Scientific Officer of Regeneron. “Regeneron is committed to fostering innovative scientific talent since we know these are the people capable of discovering and developing life-changing medical breakthroughs in the years to come.”
Two winners of the Regeneron Prize will each receive a $50,000 cash prize. The institutions nominating the two winners will also receive a donation to support their seminar series. This year’s winners are:
- Dr. Shruti Naik, The Rockefeller University, Regeneron Prize for Creative Innovation by a Postdoctoral Fellow
- Youjin Lee, Harvard University Graduate School of Arts and Sciences, Regeneron Prize for Creative Innovation by a Graduate Student
One additional Postdoctoral Fellow will be awarded an Honorable Mention and a cash prize of $10,000:
- Dr. Berenice A. Benayoun, Stanford University School of Medicine
Seven additional finalists will each be awarded $5,000.
Requests for applicants were distributed to academic institutions in November 2014. Each institution was asked to nominate two graduate students and two postdoctoral fellows. Each nominee’s submission includes a proposal explaining the nominee’s “dream” project in biomedical research, which offers insight into the nominee’s creativity and ability to think independently as a scientist. Submissions also include a curriculum vitae, list of publications and a review of the nominee’s productivity in their current laboratory.
“We are always impressed by the barrier-breaking approaches presented in the Regeneron Prize research proposals, and this year’s winners, honorable mention and finalists once again demonstrated innovative thinking and passion,” said Susan Croll, Ph.D., Regeneron scientist and Director of the Regeneron Postdoctoral Training Program. “We congratulate them and look forward to following their promising careers.”
Shares of Regeneron Pharmaceuticals closed yesterday at $516.59 . REGN has a 1-year high of $544 and a 1-year low of $269.50. The stock’s 50-day moving average is $505.72 and its 200-day moving average is $449.81.
On the ratings front, Regeneron Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on June 16, Piper Jaffray analyst Edward Tenthoff reiterated a Hold rating on REGN, with a price target of $484, which implies a downside of 6.3% from current levels. Separately, on June 15, RBC’s Adnan Butt reiterated a Buy rating on the stock and has a price target of $550.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Edward Tenthoff and Adnan Butt have a total average return of 29.1% and 0.1% respectively. Tenthoff has a success rate of 62.2% and is ranked #176 out of 3632 analysts, while Butt has a success rate of 51.9% and is ranked #2591.
The street is mostly Bullish on REGN stock. Out of 10 analysts who cover the stock, 7 suggest a Buy rating and 3 recommend to Hold the stock. The 12-month average price target assigned to the stock is $532.00, which represents a slight upside potential from current levels.
Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.